Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (168)

21

Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Graefen, M.

22

Time interval between neoadjuvant radiochemotherapy and surgery in rectal cancer : No impact on the pathologic complete response rate?

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2017

von Gani, C. | Zips, D.

23

No evidence for improved outcome with salvage radiotherapy for asymptomatic biochemical prostate cancer recurrence after prostatectomy by additive androgen suppression

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2017

von Garcia Schüler, H. | Guckenberger, M.

24

The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2016

von Brunner, T. | Fokas, E.

25

Association of HPV infection, p16 status, and efficacy of radiotherapy with or without cetuximab in advanced oropharyngeal squamous cell carcinoma

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2016

von Nieder, C.

26

enthalten in: Medizinische Monatsschrift fur Pharmazeuten | 2016

von Reisdorf, S.

27

Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Retz, M. | Albers, P.

28

First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Doehn, C.

29

The role of surgery for the management of resectable stage III non-small cell lung cancer

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2016

von Rades, D.

30

First-line treatment of unresectable, stage IV transitional cell carcinoma

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Ohlmann, C.